Podcasts about mounjaro

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

The "King Kong" of weight loss drugs, Mounjaro, should finally be available on the NHS. So, why are thousands of patients still waiting for a treatment that could transform their lives? Mounjaro was meant to be rolled out across the NHS in England from 23 June for those with the highest clinical need. However, a Sky News investigation has found it is only available in eight out of 42 NHS integrated care boards, prompting accusations of a "postcode lottery". Many providers will not make it available until autumn, while nearly half of NHS boards said they will cap the number of people they treat due to a lack of funding. Our science and medical correspondent, Thomas Moore, joins Niall Paterson on the Sky News Daily podcast as he investigates how the shortfall will cost the NHS and wider society. Gary, who weighs 25 stone (159kg) and has several obesity-related conditions, speaks to Thomas about the implications of being told Mounjaro is not available in his area. Producer: Emma-Rae Woodhouse and Emily Hulme Editor: Mike Bovill 

Inside INdiana Business Radio for the morning of August 5, 2025. Indiana University receives a $17 million federal grant to establish a cutting-edge brain research center for Alzheimer's. At least 26 patients sue Eli Lilly over alleged side effects of GLP-1 drugs Trulicity and Mounjaro. Also: Construction passes halfway on Rose-Hulman's Innovation Grove, Parkview Health names a new CFO, and Junior Achievement reveals its 2025 Business Hall of Fame laureates. Get the latest business news from throughout the state at InsideINdianaBusiness.com.

On July 31, 2025, Eli Lilly and Company announced topline data from the SURPASS‑CVOT trial comparing tirzepatide (Mounjaro) to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). According to the data, tirzepatide met the primary non‑inferiority endpoint for 3-point major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.92; 95.3% CI, 0.83 to 1.01), while also showing additional benefits in A1C, weight reduction, renal preservation, and a 16% reduction in all‑cause mortality (HR, 0.84; 95.0% CI, 0.75 to 0.94). In the latest episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, unpacked the top-line results of the SURPASS-CVOT trial. Eli Lilly and Company owns both drugs, which belong to the incretin class, but tirzepatide is a dual GIP/GLP-1 receptor agonist, while dulaglutide is a GLP-1 RA. The trial included over 13,000 adults with type 2 diabetes and either established cardiovascular disease or at high risk. During a median follow-up of 4.5 years, the primary endpoint, which was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, was reduced by 8% in the tirzepatide group relative to dulaglutide. However, the result did not reach statistical superiority due to the confidence interval crossing unity. Isaacs and Bellini also highlighted significantly greater A1c (-1.73% vs -0.9%) and weight loss (12% vs 4.95%) with tirzepatide. Additional prespecified analyses comparing data with the placebo-controlled REWIND trial suggest tirzepatide could offer up to 28% MACE and 39% mortality risk reduction compared to theoretical placebo—findings that hint at broader cardiometabolic benefit. Before concluding, hosts speculated about the potential subgroup analyses of interest for the trial, including heart failure and renal outcomes, as well as a brief discussion around Eli Lilly and Company's intent to submit a regulatory application for a cardiovascular indication before the close of 2025. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease. July 31, 2025. Accessed July 31, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-mounjaro-tirzepatide-gipglp-1-dual-agonist-demonstrated

In response to the article I wrote in The Times about whether I was daft for not using skinny jabs to lose weight, I thought revisiting my conversation with Johann Hari about his book Magic Pill, which extensively researched the benefits, limitations and risks of GLP-1 Agonist drugs such as Ozempic, Semaglutide, Wegovy and Mounjaro.Johann is thorough and meticulous in his research and this interview, originally broadcast in 2024, was before weight loss drugs became as mainstream and as widely prescribed as they are today.One of the experts Johann interviewed during his years of research, stated that the cultural impact of GLP-1s was as significant as the smart phone. At the time, it seemed like a very bold statement, but in the year since we spoke, I think it's hard to argue that they haven't completely changed the way we talk about weight, weight loss, diets, food and more...I'd love to hear your thoughts on this episode. Email me at office@emmaguns.com or Subscribe to my Substack and join the chat there. Hosted on Acast. See acast.com/privacy for more information.

Oprah Winfrey is returning to Australia on a speaking tour across the nation, which is sponsored by medicine company Lilly who are well-known for their weight loss drug Mounjaro.See omnystudio.com/listener for privacy information.

Inside Martha's Vineyard African American Film Festival; Reaction to Trump's sweeping new tariffs for trade partners; Diabetes drug Mounjaro shows heart benefits: Study Learn more about your ad choices. Visit podcastchoices.com/adchoices

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.Takeaways: The Surpass CVOT trial compares Mounjaro to Dulaglutide.Dulaglutide has shown cardiovascular benefits in previous trials.The trial results indicate Monjaro is at least not inferior to Dulaglutide.There is a trend towards better cardiovascular outcomes with Mounjaro.Weight loss and glycemic control are significant benefits of Mounjaro.The trial did not include a placebo, but used a putative analysis.The results are reassuring for patients at high cardiovascular risk.The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.The hosts express enthusiasm for the potential of Mounjaro.Future discussions will delve deeper into the trial's findings.      

Inside Martha's Vineyard African American Film Festival; Reaction to Trump's sweeping new tariffs for trade partners; Diabetes drug Mounjaro shows heart benefits: Study Learn more about your ad choices. Visit podcastchoices.com/adchoices

I sit down with Dr Roberta Barretto to talk about the positives, negatives and side effects of weight loss medication.We'd like to thank this weeks sponsors Pitch Roofers, Haven and U-Test. Links to both can be found below.www.pitchroofers.co.ukwww.u-test.co.ukThis podcast is edited by Ten10 Medias www.ten10medias.com

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Biogen's sales of the partnered Alzheimer's drug Leqembi have climbed 20% in the second quarter, while CEO Chris Viehbacher dismisses rumors of disagreements with Eisai. Moderna has cut 10% of its global workforce as part of cost-cutting measures. AbbVie is celebrating the success of Skyrizi and Rinvoq, Lilly's Mounjaro shows promise in a cardiovascular trial, and there is optimism around Sarnas for therapeutic breakthroughs. Amidst industry challenges, many biopharma professionals are looking for new job opportunities.

Triforce! Episode 327! Pyrion creates a vicious The Platform-esque utopian society for pigeons, shares his story of getting onto the weight loss drug Mounjaro and shares some amazing stories of the greatest con artists! Support your favourite podcast on Patreon: https://bit.ly/2SMnzk6 Music courtesy of Epidemic Sound. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Meshel Laurie is an Australian podcaster and author who used to be 160kgs but thanks to gastric sleeve surgery and Mounjaro weight loss jabs she lost a bunch of weight. She reached out because she wants to join Kyle's fatty club and help motivate him. See omnystudio.com/listener for privacy information.

A quick 101 | the side effects and those news headlines | the longevity link | the wider concerns | slimming pills | Ozempic and fertility | muscle loss | the positives

Professor Clare Collins delves into the world of nutrition and obesity medications with Sally Badorrek, Accredited Practising Dietitian from the University of Sydney. With 25 years of clinical experience in nutrition management of chronic conditions like obesity and diabetes, Sally shares insights on the latest medications, their side effects, and the importance of a holistic approach to weight management. We discuss the science behind new obesity medications like Semaglutide and Tirzepatide, how they work, common side effects and strategies to manage them, plus the critical role dietitians play in supporting patients on these medications. Together they unpack some myths and misconceptions around obesity treatments and discuss why a team-based approach is key to long-term health gain.Listen now to gain a deeper understanding of how these medications can aid in weight management and improve overall health. Whether you're a health professional, someone navigating weight management, or simply curious about the future of obesity care, this episode offers practical insights and compassionate perspectives.No Money No Time: Food and Mood Diary for tracking dietary habitsNo Money No Time: To access the FREE Healthy Eating Quiz: Click on the top right hand 'green button' called 'How healthy is my diet'No Money No Time closed Facebook group (be sure to take the Healthy Eating Quiz first)Find an Accredited Practising Dietitian hereDo you want a more Personalised Food, Nutrient Assessment Report? Our Australian Eating Survey includes an assessment of your nutrient (vitamin and mineral) intake. Use code 'DietCheck' at the checkout for 50% off! Purchase hereAre you in a position to make donation to support our No Money No Time website? Donate here#ObesityTreatment #DietitianAdvice #WeightManagement #Ozempic #Tirzepatide #Wegovy #ObesityMedication #Sideeffects Hosted on Acast. See acast.com/privacy for more information.

In this week's Five Minute Friday, Dr. Kay dives into the hot topic of Ozempic Face — the facial volume loss and sagging that can occur with rapid weight loss from GLP-1 medications like Ozempic, Wegovy, and Mounjaro. She explains what causes these changes, how to recognize the signs, and when to take action. Learn how strategic filler placement, collagen-stimulating injectables like Radiesse, Sculptra, and Renuva, and preventative planning can help restore youthful structure and preserve your facial foundation. Whether you're just starting weight loss or already seeing changes, this episode is your guide to looking as vibrant as you feel.

Welcome back to Ozempic Weightloss Unlocked, where we dive deep into the latest science, news, and real-world impacts of Ozempic and similar medications. Today, we're unpacking the newest discoveries about these increasingly popular weight loss drugs, their benefits, their risks, and how they're changing lives and medical thinking in 2025.First, let's get current: The spotlight on Ozempic, Wegovy, and related medications has never been brighter. Texas Health reports that these drugs, originally developed to manage type two diabetes, are being prescribed off-label for weight loss. They are part of a class called GLP-1 receptor agonists, mimicking a natural hormone that reduces appetite and improves blood sugar levels.According to Buckhead Primary Care Clinic, a recent 2024 study found that people who used Ozempic for four straight years maintained an average ten percent weight loss. That is significant, showing lasting results for long-term users. Other studies, compiled by ScienceAlert and The Independent, indicate that the majority of weight lost during treatment tends to return after stopping the drug, with some regaining weight in as little as eight weeks and the average participant gaining back five and a half pounds within twenty weeks of stopping.The reasons for the regain are still being investigated. Researchers suggest the body's metabolism might adapt to weight loss in ways that make long-term maintenance challenging. Lifestyle factors like exercise, diet, and whether participants had diabetes were taken into account, but a trend of weight cycling was observed. This weight cycling—losing weight and then regaining it—has unknown long-term impacts on health, and more research is underway.Now, what about muscle and fitness? A recent analysis by UVA Health, discussed by ScienceNews and other outlets, found that while Ozempic and similar drugs are effective at shedding pounds, they do little to improve cardiorespiratory fitness, which is a critical measure of health and longevity. More concerning, patients can lose “fat-free mass” during treatment—up to fifty percent of what's lost could be muscle, not just fat. That's why experts like Dr. Liu from UVA recommend combining medication with regular exercise and adequate dietary protein, to preserve muscle and maximize well-being.On the innovation front, new delivery methods are in the pipeline. ScienceNews reports that researchers at Stanford have developed a hydrogel that, once injected with Ozempic or Mounjaro, could maintain steady drug levels for weeks, potentially reducing injections from fifty-two a year to just four. Although still in animal trials, this technology could make ongoing treatment much more user-friendly in the future.The cultural impact is also significant. As Business Insider outlines, about one in eight adults in the United States are now taking a GLP-1 medication. These drugs have helped alter the narrative around obesity, framing it as a medical condition instead of a personal failing. However, the increased popularity has led to rising cases of eating disorders tied to the medications, and some clinicians now warn about new risks for those with a history of restrictive eating or who don't need the medication medically.Another debate is brewing over guidelines for children and teens. Stat News uncovered that more than a third of those who developed pediatric obesity guidelines had financial ties to drug manufacturers, raising concerns about impartiality and the wisdom of prescribing these strong medications to young people.To wrap up, the current consensus is that Ozempic and similar drugs represent a major advancement in obesity treatment, especially for people with type two diabetes or severe obesity. However, experts stress that these medications work best when combined with lasting lifestyle changes such as healthy eating, regular exercise, and ongoing medical guidance. Weight loss medication is often not a quick fix but part of a much larger, longer-term health plan.Thank you for tuning in to Ozempic Weightloss Unlocked. For ongoing coverage and honest discussion about the future of weight loss medicine, be sure to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are reshaping how we treat obesity — but there's so much confusion and stigma. That's why we sat down with leading obesity specialist Dr. Spencer Nadolsky for an honest, empowering conversation.We break down how GLP-1s actually work, why food noise is real, and what people aren't being told about compounded semaglutide, weight regain after bariatric surgery, and long-term success.If you've felt frustrated, misunderstood, or stuck — this episode is for you. Whether you're post-op, on medication, or considering your options, this episode brings science, support, and real talk together.

If I wanted to gain back 70 pounds, I know exactly what I'd do because I've lived it. In this episode, I'm sharing the habits, behaviors, and sneaky thought patterns that kept me stuck for years…and would absolutely pack the weight back on if I let them. From zombie eating and isolating myself to living in stretchy pants and giving in to my inner fat bitch voice, we're calling it ALL out.If you've been slipping back into these patterns or feel disconnected from yourself, this episode is your wake-up call. 

Click here to text us!Hello friends! In this episode, I am delighted to have Dr. Sarah Stombaugh on the podcast. We explore the popular GLP-1 medications you may have heard about—Ozempic, Wegovy, Mounjaro—and talk about how they work, who they're designed for, and what makes them effective. We also unpack some of the concerns around these medications, including who should avoid them and what needs to be in place for long-term success.Dr. Stombaugh explains how these medications fit into a much bigger picture that includes nutrition, movement, sleep, and stress management. For women in perimenopause and menopause who are seeing changes in their weight and metabolism, this conversation offers clarity and reassurance. Whether you've struggled with weight your whole life or are seeing shifts for the first time, you'll find helpful information here.We also talk about Dr. Stombaugh's excellent online resource, The GLP Guide, created to support people using these medications outside of a comprehensive care program.Dr. Stombaugh's approach is science-based, compassionate, and refreshingly practical. I think you're going to love what she shares.Show Notes:Grab the Breakfast Guide Here!Connect with Sarah Stombaugh, MD on:Dr. Stombaugh's GLP GuideDr. Stombaugh's InstagramDr. Stombaugh's Tiktok Dr. Stombaugh's FacebookConquer Your Weight Podcast - AppleConquer Your Weight Podcast - SpotifyWays to Connect with Me:InstagramLinkedInWebsiteYouTube...Are you a professional woman over age 50 who's ready to lose weight for the last time? Join the Vibrant-MD weight loss course.Not sure if the Vibrant-MD weight loss course is right for you? Schedule a time to talk with Dr. Heather Awad directly to learn more.Sign up for our FREE course to get the step-by-step roadmap to permanent weight loss. You'll get a new formula that truly works for professional women over age 50, because it's long overdue that we say GOODBYE to the lousy old counting games.

GLP-1 medications like Ozempic (semaglutide), Wegovy, and Mounjaro (tirzepatide) have transformed treatment for type 2 diabetes and weight loss — but they can also cause digestive side effects like nausea, diarrhea, constipation, bloating, and stomach pain that leave many patients confused or worried. In this episode, we're joined by Dr. Catherine Hudson from LSU Health New Orleans to separate fact from fiction and provide clear, evidence-based guidance. Dr. Hudson breaks down: How GLP-1 receptor agonists work Common digestive side effects—and how to manage them Why lifestyle changes still matter What you need to know before surgery or GI procedures when taking these medications Whether you're a patient, caregiver, or healthcare provider, this episode offers practical insights to help you navigate the GLP-1 journey with confidence. This episode is presented in collaboration with the American College of Gastroenterology's Patient Care Committee.  

Weight loss injections are a huge story in the diet world right now. This is a special episode of the podcast, where we hear from people who have experience of using the Mounjaro and Wegovy jabs. You'll get stories from people have had good, bad and every other kind of experience with injections. Some of our contributors have got their jabs via the NHS, others have sourced them privately. We have information about the costs involved, should you want to do the same. Plus we hear from people who have chosen not to try the jabs and why. Send us a voicenote: 07468 286104 If you'd like to mark your weight loss with our exclusive certificates, get Extra Portions of this podcast and win CASH PRIZES go to patreon.com/noshameinagain or find us on the Patreon app. Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

Welcome to my Summer Throwback Playlist—a handpicked collection of the most downloaded episodes of the podcast. These are listener favorites, packed with insights, laughs, and empowered eating encouragement to keep you fueled all summer long. A quick heads up: since these are throwbacks, you might hear old references to programs or events that are no longer active—but the heart of each episode still hits. Let's dive in and revisit the best of the best! In this episode, we're diving into one of the most talked-about weight loss medications on the market: Ozempic—also known by names like Wegovy and Mounjaro. You've likely seen the buzz: celebrity endorsements, dramatic TikTok before-and-afters, and headlines calling it a “miracle drug.” I've had clients take it, ask about it, swear by it, and question it. I've also heard from colleagues with very strong opinions on both sides. So, what's the truth? What is Ozempic really designed for? How does it work? Does it actually help with weight loss? And most importantly—is it safe? I'm sharing a brief overview of the science, my clinical observations, and why this conversation matters—especially in a world where body image, quick fixes, and long-term health often clash. ⚠️ Trigger Warning: If you're currently struggling with or recovering from an eating disorder, please listen with care or consider skipping this episode. Ozempic is contraindicated for anyone with a history of eating disorders. Want to go deeper? I reference two excellent episodes that continue this conversation: "Science Vs." and "Honestly".

What if We're Using GLP-1 Medications All Wrong?Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we're not harnessing their full therapeutic potential?In this eye-opening conversation, Dr. Ben Bikman, metabolic health researcher and professor at BYU, joins Dr. Bret Scher to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health.Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach:Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbsUsing the medication as a temporary metabolic tool to support transitions to lower-carb dietsReducing long-term risks such as muscle loss, mood changes, and diminishing effectivenessEmphasizing the importance of habit change, insulin regulation, and muscle preservationThis conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies.

Dr. Andrew Rochford joins the show to give an anonymous host some advice on Mounjaro overdosing and how to stay on top of you and your family's health this winter. Meanwhile, Wippa makes a bold prediction—that everyone will have superpowers within the next five years.See omnystudio.com/listener for privacy information.

Broadcast from KSQD, Santa Cruz on 7-10-2025: Dr. Dawn responds to an email about lion's mane mushroom blood thinning properties. Lion's mane contains hericenones that inhibit platelet aggregation but promote nerve cell growth. People on blood thinners like Eliquis or those with bleeding disorders should stop these supplements before surgery. She recommends lion's mane for cognitive preservation effects despite bleeding risks, emphasizing the need to balance benefits versus risks. An emailer asks about Fatty15 (C15:0 pentadecanoic acid) supplements marketed for longevity. Dr. Dawn finds promising research, however, most studies are in animals with limited human data. She warns against over-supplementation and recommends food-first approaches, suggesting cheaper alternatives like berberine may provide similar benefits. A visiting guest asks about continuing L-arginine after blood pressure normalized. Dr. Dawn recommends continuing L-arginine as it helps produce nitric oxide and prevents age-related arterial stiffening. She explains how blood vessel elasticity decreases with age, creating feed-forward cycles leading to permanent hypertension. The guest also asks about iodine safety - Dr. Dawn confirms 1mg daily is safe, noting Japanese populations consume up to 4mg daily without problems. Another visiting guest inquires about memory-boosting supplements (nootropics). Dr. Dawn identifies nicotine and caffeine as effective options, mentioning she uses nicotine patches for test-taking focus. She discusses lion's mane as effective for cognitive enhancement and coffee blends combining both ingredients. A caller asks about tirzepatide (Mounjaro) for weight loss at age 73, concerned about muscle loss. Dr. Dawn emphasizes the importance of branched-chain amino acids and 20-30 grams of protein before exercise for older adults to build muscle protein. She explains younger people can build muscle while fasting, but older adults need circulating protein during exercise to activate muscle-building DNA. She recommends alternating upper and lower body workouts and checking testosterone levels. Another caller asks about rapid resting pulse rate (80-100 bpm) at age 74. Dr. Dawn suggests checking blood pressure, as low blood pressure can cause compensatory heart rate increases. She explains age-related changes in blood vessel reflexes that can cause blood pooling in legs and orthostatic changes. The caller also complains about pharmaceutical advertising, prompting Dr. Dawn to criticize direct-to-consumer drug marketing for creating artificial needs through emotional manipulation. Dr. Dawn warns against P-Tau217 blood testing for Alzheimer's screening, calling it inadequate for general population screening. The test has poor predictive value below level 10, creating many false positives in low-risk populations. She criticizes associated drugs like donanemab (Kisunla) for severe side effects including brain swelling and hemorrhage. Instead, she recommends lifestyle interventions: exercise, stress control, adequate sleep, reduced alcohol and sugar intake for memory concerns. She criticizes FDA approval of a new blood test for colon cancer screening with 83% sensitivity for detecting existing cancers but poor sensitivity for precancerous polyps. Dr. Dawn criticizes this as inadequate screening since it detects cancer after "the horse has left the barn" rather than preventing it. In closing remarks with her impromptu guests, Dr. Dawn addresses a question about intermittent fasting and exercise timing. She explains that exercising while fasting provides cardiovascular benefits but won't build muscle mass in older adults. She recommends bioimpedance analysis testing to track lean body mass annually in seniors and emphasizes the importance of progressive resistance training to prevent age-related muscle loss.

Ozempic continues to dominate conversations about weight loss, drawing attention from both the medical community and celebrity circles over the past week. This injectable medication, originally designed to manage type two diabetes, has increasingly become known for its ability to help people shed pounds. According to information from Northwestern University published just yesterday, users of Ozempic typically see a gradual but significant reduction in body weight, with clinical trials showing average losses of ten to fifteen percent over the course of a year. For most, the medication begins to make a noticeable difference after about six to eight weeks, particularly when combined with improved diet and regular exercise. However, experts are quick to caution that Ozempic is not a magic solution; sustainable weight loss still relies on lifestyle changes such as healthy eating and physical activity.In the last week, the public conversation around Ozempic has taken on new dimensions. One of the most visible aspects is its popularity among celebrities. According to coverage in the Financial Express from July seventh, high-profile users like Oprah Winfrey, Sharon Osbourne, Whoopi Goldberg, and Rebel Wilson have shared their experiences with Ozempic. Their stories have contributed to the drug's reputation as Hollywood's preferred method for rapid, dramatic weight reduction. However, this visibility has also drawn attention to some unexpected consequences. Dermatologists report an uptick in people experiencing what is now being called Ozempic mouth, a condition marked by significant volume loss and increased wrinkles around the mouth and jawline, which can result in an aged appearance. The rapid loss of facial fat has caused some to seek cosmetic treatments like dermal fillers or skin-tightening procedures to counteract these effects.Oprah Winfrey has been especially vocal and candid about her Ozempic journey in the past week. Reports from Deaconess Health and SheFinds note that Oprah has discussed the medication's role in her recent forty-pound weight loss, which she has attributed to Ozempic, healthy eating, and consistent exercise. During her recent trip to Venice for a celebrity wedding, Winfrey was photographed sporting a noticeably slimmer physique while working out with Gayle King. Fans on social media praised her transformation, and Winfrey herself has emphasized the importance of pairing any medication with dedication to overall well-being. Furthermore, Oprah recently hosted a "State of Weight" panel as part of her ongoing efforts to foster open discussion about weight loss, the struggles involved, and the tools that can help.While Ozempic maintains its position as a popular weight loss solution, new research published in The New England Journal of Medicine and reported by both HealthDay and AOL this week has challenged its supremacy. The study found that another medication, tirzepatide sold under the names Mounjaro and Zepbound, is even more effective at promoting weight loss. Participants taking tirzepatide averaged a twenty percent reduction in body weight, while those on Ozempic averaged about thirteen percent. Experts note that tirzepatide works on two hormone receptors instead of one, which seems to explain its stronger effect. Despite these new findings, Ozempic's influence remains powerful because of its proven track record and cultural prominence.Still, significant safety concerns persist regarding Ozempic's use for weight loss. The Motley Rice law firm and other health sources have reported ongoing lawsuits related to serious side effects, including gastrointestinal issues and, in rare cases, vision loss. Moreover, many patients regain much of the weight they lost if they discontinue the medication, pointing to the need for ongoing management and support rather than quick fixes.In summary, the past week has seen Ozempic's celebrity power and medical potential both celebrated and scrutinized. Oprah Winfrey's openness continues to resonate with many, highlighting that while medications like Ozempic can be helpful tools, the broader journey of weight management demands a holistic approach. The emergence of alternatives such as tirzepatide may shift the landscape, but one message remains clear from experts and high-profile users alike: sustainable weight loss requires lasting lifestyle change, not just a prescription.Thanks for listening, please subscribe, and remember—this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Resources for the Community___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials United States Patent & Trademark Office Website and Email https://www.uspto.gov/usptoinfo@uspto.govi-MAK Websitehttps://www.i-mak.org/i-MAK Briefs & Reports https://www.i-mak.org/resource-type/briefs/______________________________________________________________________Tahir Amin, founder of I-MAK, joins us to break down why GLP-1 meds like Ozempic and Mounjaro stay so pricey. We dig into evergreening, patent thickets, and how pharma companies use legal loopholes to delay generics and extend monopolies.We also explore why some companies spend more on stock buybacks than drug innovation—and what that means for access. If you've felt exploited by the system, you're not alone. But there's hope. Learn about the policy changes ahead and how you can take action to fight for affordable meds.Tahir Amin bio:Tahir Amin is a founder and CEO of the Initiative for Medicines, Access & Knowledge (I-MAK), a nonprofit organisation working to address the systemic inequities in how medicines are developed and distributed. He has over 30 years of experience in intellectual property (IP) law, during which he has practised with two of the leading IP law firms in the United Kingdom and served as IP Counsel for multinational corporations. His work focuses on changing the structural power dynamics that allow health and economic inequities to persist by challenging and re-shaping IP laws and the related global political economy to better serve the public interest.  He is a former Harvard Medical School Fellow in the Department of Global Health & Social Medicine and has served as legal advisor/consultant to many international groups, including the European Patent Office and World Health Organization, as well as testifying before the U.S. Congress on intellectual property and unsustainable drug prices.Special Guest Co-Host, Amanda Bonello from GLP-1 Collective https://glp1collective.org/ _______________________________Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

Haben wir uns tatsächlich grundlos durch Brigitte-Diäten und David Kirsch-Eier gequält? Intervallfasten, Kohlsuppendiät, fettarme Leberwurst und Wandpilates – das soll alles umsonst gewesen sein? Der edelste Tropfen zwischen Hollywood und dem Main-Kinzig-Kreis heißt Mounjaro, Ozempic, Wegovy oder Saxenda. Für Adipositaspatient:innen rückt ein gesundes Gewicht in greifbare Nähe, Influencerinnen posten ihre mageren Schlüsselbeine. Also wo ist der Haken? Haben wir abgefragt. Wer bekommt die Spritze? Was ist mit Nebenwirkungen? Muss man das Zeug ewig nehmen? Ist Schlanksein jetzt was für Reiche? Wann gibt es das Zeug auf Rezept? Können Sportstudios jetzt dicht machen? Und ist die seidige Silhouette aus dem Kwikpen nur eine kurzfristige Modeerscheinung, oder können die Klamottenketten Größe 42 demnächst aus den Regalen räumen? Und wo zum Teufel ist denn Body Positivity hin? Diese Folge ist euer All Inclusive-Paket für alles rundum den sexy Body aus der Kanüle. Tanja Marfo postet seit Jahren Content rund um Selbstakzeptanz außerhalb des Normgewichts. Als sie selbst bei 240 Kilo war, hat sie die Notbremse gezogen. Erst ein Schlauchmagen, jetzt Mounjaro. Aber der Weg zu einem gesunden Gewicht ist deutlich schmerzhafter als ein kleiner Piks ins Bauchfett. Markus Grill hat zusammen mit dem Recherchenetzwerk von NDR, WDR und Süddeutscher Zeitung dem Phänomen Abnehmspritze auf den Zahn gefühlt. Warum sind so viele Medizinerinnen und Mediziner komplett aus dem Häuschen, wenns um diese Schlankmacher geht? Und was wäre, wenn's die Spritze auf Rezept gäbe? Spoiler: Wär gar nicht mal so geil. Dr. Andreas Klein ist Medizinethiker und gehört zum Zukunftsinstitut. Für ihn und seine Kolleg:innen ist die Abnehmspritze bereits die Zeitung von gestern. Seiner Meinung nach sind die Präparate gekommen, um zu bleiben. Aber wär das denn so schlimm? Ehrlicherweise sind wir ein bisschen stolz auf diese Folge. Macht es nicht kaputt! Und eins noch: Wir lieben jedes Pfund an euch! Und hier noch die Links fürs kleine Rabbit Hole vorm Schlafengehen: https://assets.ctfassets.net/sadqqidhqb2f/7revxW7gt8aDhDPwWmtfdN/149a4dfd7937eeeb1368ab7632b603bc/EFPIA_2024_Germany.pdf https://www.novonordisk.de/content/dam/nncorp/de/de/transparenz/2023/offenlegung-spenden-sonstige-2023-final-mzzu.pdf https://www.ndr.de/ratgeber/gesundheit/Ozempic-Fuer-wen-eignet-sich-die-Abnehmspritze-,adipositas170.html Und das hier legt euch vor allen Dingen Anne ans Herz, die eine parasoziale Beziehung mit Super Mario führt: Cheats https://www.ardaudiothek.de/sendung/cheats-wer-zerstoert-counter-strike/urn:ard:show:16d7f8950e911f8c/

Welcome to Ozempic Weightloss Unlocked, your source for the latest developments, insights, and real stories about Ozempic and the world of weight loss medications. Let's dive right in.The conversation around Ozempic remains as lively as ever in 2025. While Ozempic, or semaglutide, was originally created to manage type two diabetes, it quickly garnered attention for its remarkable ability to support significant weight loss. According to Toronto Life, this drug, which started as a diabetes treatment, has proven in multiple clinical trials to help some people lose up to twenty percent of their body weight when taken at higher doses, a result that validates obesity as a medical condition instead of just a lifestyle issue.A 2024 study highlighted by Drugs.com compared Ozempic to Mounjaro, another medication in the same class. Both were found effective, but Mounjaro showed even greater weight loss results, with eighty-two percent of patients losing at least five percent of their body weight, compared to sixty-seven percent for Ozempic. Importantly, these medications work by mimicking gut hormones to curb appetite and help with blood sugar control, but Mounjaro targets an additional hormone, which might explain the stronger effect.Clinical trials published in The Lancet have found participants using Ozempic experience an average drop of twelve to fourteen percent in body weight. And as reported by USF Blogs, real user stories show individuals can lose upwards of fifty pounds in a year, especially when combined with lifestyle changes. That brings us to a key point: Ozempic is most powerful when used alongside healthier eating and more physical activity. Fay Nutrition emphasizes that initial results might feel modest, with three to four percent weight loss in the first month for most people, but those who change their habits see the biggest long-term benefits.The rise of semaglutide-based treatments is fundamentally changing how health systems like the NHS treat obesity. In the United Kingdom, both Ozempic and its higher-dose sibling Wegovy are now routinely prescribed not just for diabetes but also for weight management. Over three million prescriptions are now issued annually in the NHS, making these drugs a staple of weight-related health care.But while the benefits are clear, there is growing attention on side effects and the need for responsible use. King Law reports that over eighteen hundred lawsuits have been filed in the United States, with issues ranging from slowed digestion to pancreatitis and even severe kidney injuries. The Food and Drug Administration has updated Ozempic's safety labeling to reflect these risks. Experts stress it is critical to use these drugs under proper medical supervision, especially with reports of non-doctors prescribing them illegally.On the medical front, research published in NEJM Evidence and covered by Live Science now suggests that semaglutide may benefit people with type one diabetes as well, broadening its potential impact in ways only just being explored.Beyond blood sugar and weight, Ozempic may also offer unexpected benefits. Dr. Aliabadi points out that some individuals report reduced cravings for alcohol while taking GLP-1 drugs, opening the door to new treatments for addiction in the future. The science is still developing, but it's another intriguing avenue for this class of medication.As new drugs like orforglipron enter the scene, delivering results that rival or surpass Ozempic, the landscape of medical weight loss continues to evolve rapidly. The one constant? While medications can be transformative, sustainable health always relies on a foundation of healthy choices and informed medical guidance.Thanks for joining us for another episode of Ozempic Weightloss Unlocked. Be sure to subscribe to stay up to date on the latest news, research, and real-life stories. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

This week, we're diving into the stories shaping what we eat, how we shop and the way we live. We're talking about the government's new push to tackle obesity by cutting just 50 calories a day, whether weight-loss jabs like Wegovy and Mounjaro are already changing our shopping habits, and the latest on possible bans or tighter rules for alcohol advertising in the UK. We also get into which oils you actually want to be cooking with at home, why M&S has just trademarked something called “Punishment Juice,” and a major new NHS survey that reveals one in four young adults are now living with a mental health condition. Plus, could creatine help prevent Alzheimer's? We look at what the science says so far — along with all our personal updates and this week's recommendations, from cult podcasts to berry-packed smoothies. This week's recs: Korean exfoliating mitt⁠ ⁠How I Became a Brainwashed Cult Bride⁠ on Conversations (ABC Australia) Get your copy of Rhi's new book 'The Unprocessed Plate' ⁠⁠HERE⁠ Vote for us to win the Listener's Choice award at the British Podcast Awards: https://www.britishpodcastawards.com/voting Learn more about your ad choices. Visit podcastchoices.com/adchoices

Send us a message with this link, we would love to hear from you. Standard message rates may apply.On this episode discuss the side effects of GLP-1 medications like Ozempic and Wegovy, Zepbound, and Mounjaro offering practical strategies to manage these effects while still benefiting from the medications.• GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) help manage type 2 diabetes, obesity, and can reduce cardiovascular risk• Most common side effects are gastrointestinal: nausea, vomiting, diarrhea, bloating, and constipation• "Sulfur burps" are a frequently reported side effect that some manage with Pepto-Bismol• Start with low doses and increase slowly to minimize side effects• Eat smaller portions, avoid greasy/spicy foods, and practice mindful eating to reduce GI symptoms• Stay hydrated and increase fiber intake to prevent constipation• Gallbladder problems and pancreatitis risk may increase with rapid weight loss• Some evidence suggests potential vision changes requiring regular eye check-ups• Medications like insulin or blood pressure drugs may need adjustment when on GLP-1s• Most side effects improve with time as your body adjusts to the medicationSend us an email at yourcheckuppod@gmail.com or visit our Instagram or website to stay updated with weekly episodes released every Monday.Support the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

Send us a textWhat happens when you've been using food to manage your emotions but, since you're on a GLP-1 medication, you can't do it anymore?Thanks for listening, I hope this episode will be helpful.Philippe

GLP-1 Weight Loss: Fat or Muscle? What Women Must KnowGLP-1 and the Skinny Fat Trap: How to Avoid Muscle LossAre GLP-1 weight loss drugs like Ozempic, Wegovy, or Mounjaro making you skinny fat? If you're seeing the scale go down—but losing strength, shape, and energy—you're not alone.In this video, I break down what the research really says about GLP-1 medications and why up to 40% of the weight lost may be from muscle, not fat. I'll also show you exactly how to protect your metabolism and stay strong during your weight loss journey.As an IFBB Fitness Pro and women's fitness coach with over 20 years of experience, I've helped thousands of women lose fat, build lean muscle, and feel confident in their bodies—at every stage of life, including menopause.✅ What you'll learn:- The truth about GLP-1 and muscle loss- How to avoid the “skinny fat” trap- The best strength training strategies- Protein goals that actually work- Recovery tips for better results- Why women over 40 need a different approach

GLP-1's are tools and if you don't use them well, there's a cost. I'm a registered dietitian, speaker and author who works in the weight loss and GLP-1 space. Here are the 3 most important nutrition pitfalls to avoid if you want to feel your best on a GLP-1 like Ozempic, Mounjaro, Zepbound, & Wegovy.

In this informative and compassionate episode, Bonnie breaks down the rising popularity of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) specifically as they relate to weight loss. She dives deep into how they work, why they're being so widely prescribed, what the research actually says, and the often-overlooked risks and implications, especially around nutrition, food noise, and long-term health. Whether you're considering a GLP-1, currently on one, or feeling confused and conflicted, this episode offers grounded insights, body autonomy, and a non-judgmental space for informed decision-making.In this episode, you'll learn:How GLP-1 medications work to suppress appetite and delay stomach emptyingThe key difference in dosing between diabetes management and weight loss useWhy weight regain is common after stopping these medicationsThe connection between GLP-1 use, food noise, and eating disordersWhy prioritizing nutrition is critical—especially if you're using a GLP-1What this movement gets right—and what it missesRisks, side effects, and long-term unknowns of GLP-1 useHow to do a personal risk-benefit analysis rooted in body autonomyQuestions answered in this episode:What are GLP-1 medications, and why are they being used for weight loss?How do these drugs affect hunger, fullness, and food thoughts?Are there side effects or long-term risks with using GLP-1s for weight loss?What does the research actually say about their effectiveness and safety?Can these meds be harmful for someone with a history of disordered eating?What should I consider if I'm thinking about starting (or stopping) a GLP-1?How can I support a friend or loved one who is on one of these medications?Mentioned in this episode:Listen to episode 173: Quiet The Food Noise: 3 Ways Intuitive Eating Can HelpGLP-1 Informed Consent from Medical Students for Size Inclusivity DownloadFollow Regan Chastain's work: https://weightandhealthcare.substack.com/ Ready to Heal Your Relationship with Food?My team of registered dietitians is now accepting insurance for one-on-one nutrition counseling! Spots are limited, so if you're ready to start your journey toward food freedom, visit https://dietculturerebel.com/insurance to learn more!Connect with Bonnie on Instagram: @diet.culture.rebel

Is there a better, safer, FREE alternative to Ozempic (and other GLP-1 drugs)? In this episode of Walk, Don't Run to the Doctor, Miles Hassell MD reacts to the growing buzz and shares a time-tested, evidence-based 3-step plan that outperforms popular weight loss drugs in the long run. As GLP-1 drugs like Ozempic, Wegovy, and Mounjaro surge in popularity, Dr. Hassell offers critical insight into their risks—like muscle loss, pancreatic complications, and long-term unknowns—while proposing a practical, natural alternative for lasting weight loss and better metabolic health. Key Takeaways: Why Big Pharma's track record with weight loss drugs demands caution The secret 3-step plan: Eat 6 servings of fruits & veggies, 3 minutes of daily exercise, reduce refined carbs Bonus tips: Bust cravings by eating protein with every meal, daily probiotics, and unlock the power of preemptive eating Why this plan costs nothing, has zero side effects, and starts showing results in just one week A timely message in light of the weight loss drug headlines—who should be in control of your health?  More references can be found at www.GreatMed.org Get your copy of Good Food Great Medicine. https://a.co/d/ajAzYzo Would you like Dr. Hassell to answer your question on the air? Contact us! Phone/text: 503-773-0770 e-mail: info@GreatMed.org Write us a letter. We love to hear from you. This podcast is sponsored by our generous listeners. Send questions, comments, and support to: 4804 NW Bethany Blvd., Suite I-2, #273 Portland OR 97229 References: Chen, X., et al. (2025). Association of dietary fiber intake with all-cause and cardiovascular mortality in diabetes and prediabetes. Diabetology & metabolic syndrome, 17(1), 231. https://pubmed.ncbi.nlm.nih.gov/40533827/   Look, M., et al. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, obesity & metabolism, 27(5), 2720–2729. https://pubmed.ncbi.nlm.nih.gov/39996356/   Wilding, J., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989–1002. https://pubmed.ncbi.nlm.nih.gov/33567185/   Tinsley, G. M., & Heymsfield, S. B. (2024). Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments. Journal of the Endocrine Society, 8(11),https://pubmed.ncbi.nlm.nih.gov/39372917/    Neeland, I. J., et al. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes, obesity & metabolism, 26 Suppl 4, 16–27. https://pubmed.ncbi.nlm.nih.gov/38937282/   Sato, M., et al. (2023). Relationships among Postprandial Plasma Active GLP-1 and GIP Excursions, Skeletal Muscle Mass, and Body Fat Mass in Patients with Type 2 Diabetes Treated with Either Miglitol, Sitagliptin, or Their Combination: A Secondary Analysis of the MASTER Study. Journal of clinical medicine, 12(9), 3104. https://pubmed.ncbi.nlm.nih.gov/37176545/   Monami, M., et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, obesity & metabolism, 19(9), 1233–1241. https://pubmed.ncbi.nlm.nih.gov/28244632/   Anderson, S. L., & Trujillo, J. M. (2010). Association of pancreatitis with glucagon-like peptide-1 agonist use. The Annals of pharmacotherapy, 44(5), 904–909. https://pubmed.ncbi.nlm.nih.gov/20371755/   Kapoor, I., Sarvepalli, S. M., D'Alessio, D., Grewal, D. S., & Hadziahmetovic, M. (2023). GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Survey of ophthalmology, 68(6), 1071–1083. https://pubmed.ncbi.nlm.nih.gov/37454782/   Bikou, A., et al. (2024). A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert opinion on pharmacotherapy, 25(5), 611–619. https://pubmed.ncbi.nlm.nih.gov/38629387/   Jalleh, R. J., et al. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of clinical endocrinology and metabolism, 110(1), 1–15. https://pubmed.ncbi.nlm.nih.gov/39418085/   Berg, S. AMA. (2023). Questions patients may have about weight-loss drugs. https://www.ama-assn.org/delivering-care/public-health/questions-patients-may-have-about-weight-loss-drugs   Friedman, J. (2025). America's up-and-down history with weight-loss drugs. https://www.history.com/articles/weight-loss-drugs-america    

Sorry about the background noise. I will try to record this with a better microphone, but until I can re-record it I'm gonna go ahead and put this one up so you can get the meat of the subject. ✍️ EPISODE DESCRIPTION What are GLP‑1s, really? If you've heard the buzz around Ozempic, Wegovy, Mounjaro—or seen headlines claiming they're weight loss miracles—you need to listen to this deep dive before jumping on the bandwagon. In this episode, we break down: What GLP‑1s actually are (hint: yes, they're hormones) Why they work for weight loss and blood sugar control Pros, cons, and legit side effects no one talks about “Ozempic face,” muscle loss, and the long-term cost of shortcuts The truth about hormone therapy (and the hypocrisy of shaming it) Where the research is headed—fertility, mental health, inflammation, and beyond ⚠️ Spoiler: If you're using these meds, you're on hormone therapy. That's not a bad thing—but let's stop pretending it's not what it is. Whether you're curious, concerned, or already prescribed one—this episode gives you facts over fear and the full picture you won't get from TikTok.

In this edition of The Naked Scientists, weight loss jabs being prescribed by GPs in England, but do we know enough about the side effects? Also, a new simple test to replace endoscopies for patients with Barrett's oesophagus. And we hear from one of the engineers at the Vera Rubin Observatory, which is shedding new light on the cosmos... Like this podcast? Please help us by supporting the Naked Scientists

In this episode, we dive into the buzzy world of GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) and how they might do more than just curb appetite, they might help you lose the desire to drink altogether. Dr. Brooke breaks down the science behind how these medications impact your brain's reward system and why they might be a game-changer for the sober-curious. ✨ HIGHLIGHTS: – What exactly are GLP-1s, and how do they work in the body – How these meds may reduce alcohol cravings and “cut the loop” of reward-seeking – Why people on GLP-1s often feel like their drinking habits shift naturally – The double-edged sword: why it's not a magic bullet and how deeper healing still matters – The future of biohacking sobriety with food, supplements, and yes—medications

From weight medication side effects to the best exercises to build muscle as you age. Ask us anything. We’ve got you covered In this episode, Dr Mariam and Claire Murphy answer all your questions about the body. From whether the BMI is bullshit to knowing what a healthy weight range is. Plus, what’s the right age to start getting bone density checks? They also talk to the experts to answer questions about whether genetics impact your weight and whether you need a special diet and exercise plan if you’re prescribed weight loss medication. They also discuss what kinds of health issues can be reversed if you lose weight and how we reframe conversations about our body. THE END BITS For more information on bone density: Healthy Bones Australia Sign up to the Well Newsletter to receive your weekly dose of trusted health expertise without the medical jargon. Ask a question of our experts or share your story, feedback, or dilemma - you can send it anonymously here, email here or leave us a voice note here. Ask The Doc: Ask us a question in The Waiting Room. Follow us on Instagram and Tiktok. All your health information is in the Well Hub. Support independent women’s media by becoming a Mamamia subscriberCREDITS Hosts: Claire Murphy and Dr Mariam Guest: Dr Isobelle Smith Guest: Dr Jessica McEwan Guest: Dr Sonia Davison Senior Producers: Claire Murphy and Sasha Tannock Audio Producer: Scott Stronach Mamamia studios are styled with furniture from Fenton and Fenton. Visit fentonandfenton.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present, and extend that respect to all Aboriginal and Torres Strait Islander cultures.Information discussed in Well. is for education purposes only and is not intended to provide professional medical advice. Listeners should seek their own medical advice, specific to their circumstances, from their treating doctor or health care professional.Support the show: https://www.mamamia.com.au/mplus/See omnystudio.com/listener for privacy information.

En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street sube pese a tensiones en Medio Oriente: Futuros en verde: $SPX +0.8%, $US100 +1.2%, $INDU +0.8%. Los rendimientos del Treasury caen levemente. Israel acusó una violación del alto al fuego y amenaza con represalias, mientras Irán niega nuevos ataques. El permiso para civiles de abandonar refugios en Israel trajo algo de alivio. Hoy se publican datos de precios de vivienda, confianza del consumidor y testifica Powell en el Congreso. • IBM despliega sistema cuántico avanzado en Japón: $IBM y el laboratorio RIKEN inauguraron el primer IBM Quantum System Two fuera de EE.UU., ubicado en Kobe. El sistema utiliza el procesador Quantum Heron de 156 cúbits, el más avanzado de la compañía. Apoyado por NEDO, el proyecto busca combinar supercomputación y computación cuántica en la era post-5G. • Novo Nordisk lanza Wegovy en India: $NVO presentó oficialmente su medicamento para pérdida de peso en el mercado indio. Wegovy se venderá en cinco dosis, con un costo mensual entre $50 y $312. La competencia con $LLY se intensifica tras el lanzamiento de Mounjaro en el país. $NVO +1.95% premarket. • Mastercard y Fiserv integran stablecoin FIUSD: $MA fortalece su alianza con $FI al integrar la stablecoin FIUSD en su red global. La plataforma digital de Fiserv se lanzará en 2025 y busca facilitar soluciones para bancos y adquirentes. $FI +6% premarket tras el anuncio. Una jornada con atención en geopolítica, avances tecnológicos y nuevos frentes en salud y pagos digitales. ¡No te lo pierdas!

Morse code transcription: vvv vvv Met Police chief shocked by planned Palestine Action protest in London Our sister died because of our mums cancer conspiracy theories, say brothers What is the Strait of Hormuz and why does it matter Vera Rubin First celestial image from revolutionary telescope How the US says it hit Irans nuclear sites Mounjaro weight loss jab available at GPs to select few Russias economy is down but not out The Christians drummer has cardiac arrest on Liverpool waterfront stage Bride shot dead in attack on wedding party in south east France Man charged with murder of woman after Stoke Newington gas blast

Welcome back to Diamond Paint and Podcast — where I ramble, reflect, and real-talk my way through a diamond painting session.In this episode, we're all over the place in the best way possible. I'm chatting about:The “Donut Mom” at cheerleading

It's only June. That means you still have six full months to change your life. Seriously. Who do you want to be when the ball drops on December 31st?Are you going to be crying in the bathroom again because nothing fits? Googling “how to lose weight fast” for the hundredth time? Or are you going to feel proud as hell that you didn't give up on yourself this time?In this episode, I'm talking about what's actually possible in six months and how showing up with consistency (not perfection!) can transform how you feel, how you live, and how you see yourself.If you're tired of starting over every Monday, hating your life, emotionally eating your days away, and waiting for “the right time,” this is your wake-up call.Let's talk about who you could be by the end of the year and how to start becoming her now.

Nadine Dorries is one of the most recognisable Conservative politicians from the past two decades. Elected as the MP for Mid Bedfordshire in 2005, she notably clashed with David Cameron and George Osborne (who she called ‘two arrogant posh boys') and lost the whip in 2012 when she took part in the reality show I'm A Celebrity, Get Me Out Of Here. Loyal to Boris Johnson, she served in his government and rose to be Culture Secretary. She stood down in 2023 and went on to write about politics in the bestselling books The Plot and Downfall.On the podcast, Nadine tells the Spectator's executive editor Lara Prendergast about her memories of tinned burgers and Sunday lunches as a child, working long shifts as a nurse in Warrington and what it was like spending a year in Zambia. She also explains the ‘relentless' but ‘collegiate' atmosphere of Parliament and how she once saw a mouse at the Commons' salad bar. Nadine explains what it is like to have recently used the weight-loss jab Mounjaro and why, in her family, she is still the ‘queen of the Sunday roast'.Produced by Patrick Gibbons. Hosted on Acast. See acast.com/privacy for more information.

In this powerful and unapologetic episode, I sit down with Dr. Tyna Moore — physician, author, and outspoken advocate for evidence-based metabolic health — for a deeply candid conversation about peptides, GLP-1s (like Ozempic, Mounjaro, Wegovy, and Zepbound), and why the current medical system is failing women. We dive into: